SCHEMBL17325095

SCHEMBL17325095

Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1/C=C/c1cnc2[nH]c(=O)ccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 8/20 0.62
▸ ABL1 P00519 5/20 0.60
▸ EGFR P00533 6/20 0.60
▸ BRAF P15056 5/20 0.60
▸ KIT P10721 1/20 0.57
▸ FGFR1 P11362 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ PDGFRA P16234 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ FLT3 P36888 1/20 0.57
▸ LRRK2 Q5S007 1/20 0.57
▸ HDAC6 Q9UBN7 1/20 0.57
▸ MAP3K7 O43318 1/20 0.56
▸ MAP4K4 O95819 1/20 0.56
▸ RAF1 P04049 1/20 0.56
▸ LYN P07948 1/20 0.56
▸ SRC P12931 1/20 0.56
▸ EPHA2 P29317 1/20 0.56
▸ EPHB2 P29323 1/20 0.56
▸ CSK P41240 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17325094 0.97 ABL1 (0.64) RETABL1EGFRBRAFKIT
SCHEMBL18762351 0.97 ABL1 (0.64) RETABL1EGFRBRAFKIT
SCHEMBL18775248 0.91 RET (0.51) RETABL1EGFRBRAFFGFR1
SCHEMBL18775244 0.90 ABL1 (0.52) RETABL1EGFRBRAFKIT
SCHEMBL15860048 0.89 RET (0.60) RETABL1EGFRBRAFKIT
SCHEMBL17313614 0.89 RET (0.60) RETABL1EGFRBRAFKIT
SCHEMBL17325101 0.86 DDR2 (0.53) RETABL1EGFRBRAFKIT
SCHEMBL18762334 0.85 RET (0.59) RETEGFRBRAFKIT
SCHEMBL17325099 0.85 DDR2 (0.59) RETABL1KIT
SCHEMBL17325093 0.84 ABL1 (0.78) ABL1KITFGFR1CYP2C9PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349588-A1 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS NATCO PHARMA LIMITED (IN) 2017-12-07 — — US disclosed
US-9765072-B2 1H-1,8-naphthyridin-2ones as anti proliferative compounds NATCO PHARMA LIMITED (US) 2017-09-19 — — US disclosed
US-20170114057-A1 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS NATCO PHARMA LIMITED (IN) 2017-04-27 — — US disclosed
WO-2015186137-A1 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS NATCO PHARMA LIMITED (IN) 2015-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349588-A1 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS ABL1, MKI67, MCL1 RET 495/4885ABL1 1/4885EGFR 424/4885
US-20170114057-A1 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS ABL1, MKI67, ABL2 RET 503/4885ABL1 1/4885EGFR 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback